BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms
Holly Lee, Paola Neri, Nizar J. Bahlis
Abstract
ABSTRACT: Bispecific antibodies that engage T cells to target B-cell maturation antigen or G-protein-coupled receptor class C group 5 member D have demonstrated remarkable efficacy in heavily pretreated relapsed or refractory multiple myeloma (MM), leading to the recent accelerated approval of teclistamab, elranatamab, and talquetamab by health agencies. Future challenges, however, remain to define their optimal dosing schedule and duration, sequencing, and integration with established anti-MM therapeutics as well as delineating the biological and clinical mediators of immune escape.
Topics & Concepts
Multiple myelomaBispecific antibodyAntibodyMedicineImmunologyChimeric antigen receptorAntigenCancer researchImmune systemOncologyMonoclonal antibodyImmunotherapyMultiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy research